[Clinical and bacterial resistance during treatment of tuberculosis with streptomycin, PAS, TB 1 and INH].
D010131:Aminosalicylic Acid / Q000627:therapeutic use*; D001424:Bacterial Infections; D007536:Isomerism; D009525:Niacin; D009539:Nicotinic Acids / Q000627:therapeutic use*; D013307:Streptomycin / Q000627:therapeutic use*; D013882:Thiosemicarbazones / Q000627:therapeutic use*; D014376:Tuberculosis / Q000628:therapy*
D009539:Nicotinic Acids; D013882:Thiosemicarbazones; D009525:Niacin; D010131:Aminosalicylic Acid; D013307:Streptomycin
NICOTINIC ACID ISOMERS/therapeutic use; PARA-AMINOSALICYLIC ACID/therapeutic use; STREPTOMYCIN/therapeutic use; THIOSEMICARBAZONES/therapeutic use; TUBERCULOSIS/therapy
Klinische und bakterielle Resistenz im Verlaufe der Behandlung der Tuberkulose mit den neuen Tuberkuloseheilmitteln: Streptomycin, PAS, TB 1, INH.